Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity now!
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Start the activity now.
Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now!
In this free CME/NCPD activity, Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, and Nathan Pennell, MD, PhD, Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute, discuss the role of acquired resistance mutations in first-line treatment selection, the potential for central nervous system (CNS) disease, and the efficacy and safety of novel treatment options for patients with ALK-positive advanced NSCLC.
In this virtual tumor board, Vicki L. Keedy, MD, MSCI, Brian P. Rubin, MD, PhD, and Kathleen Polson, NP, discuss diagnostic evaluation, treatment selection, and supportive care strategies for patients with soft tissue sarcoma.
In this virtual tumor board, Sara M. Tolaney, MD, MPH, Ira J. Bleiweiss, MD, and Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, assess predictive and prognostic markers for MBC, evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC, and apply strategies to manage adverse events for MBC. Start now!
This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!
Learn more about emerging immunotherapies for the treatment of recurrent and metastatic cervical cancer, strategies to monitor and manage adverse events, and developments in the standard of care for patients wth cervical cancer. This activity is presented by leading experts, Bradley Monk, MD, FACS, FACOG, University of Arizona College of Medicine, and Jennifer Filipi, MSN, FNP-C, Massachusetts General Hospital. Start the activity now!
Gain expert insight and strategies for the management of differentiated and anaplastic thyroid cancer, including emerging data on immunotherapies and strategies to manage adverse events. This activity is presented by leading experts, Jochen Lorch, MD, MSc, Director of the Thyroid Cancer Center, Dana-Farber Cancer Institute, and Carolyn Grande, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center. Start now!
Sara A. Hurvitz, MD, FACP, Director of the Breast Cancer Clinical Trials Program at the David Geffen School of Medicine at UCLA, and a prominent authority on TNBC, provides perspectives on personalized care plans for patients with metastatic TNBC, efficacy and safety of emerging treatments, strategies to improve quality of life for patients with metastatic TNBC, and much more! Start the activity now!
Discover new and emerging treatment strategies for advanced classical Hodgkin lymphoma, personalized care plans, and best practices for managing supportive care need. This activity is presented by leading experts Kami Maddocks, MD, Professor of Clinical Internal Medicine, Lymphoma Program Director, The James Cancer Hospital at The Ohio State University, and Kelly Brassil, PhD, RN, FAAN, Advanced Practice Nurse, University of Texas MD Anderson Cancer Center. Start the activity now!
Anne Chiang, MD, PhD, Yale School of Medicine, a leading expert on small cell lung cancer, for an in-depth presentation on patient outcomes in extensive-small cell lung cancer. Dr. Chiang will present evidence-based advice regarding emerging therapies, strategies for targeted treatments and immunotherapy, optimization of individual patient treatment plans, managing adverse events, and much more! Start the activity now!
Learn new advances in the treatment of relapsed or refractory immune thrombocytopenia, including treatment differentiation, efficacy and safety strategies, and much more. This activity features perspectives from two noted experts in the field, Dr. Keith McCrae, Director of Benign Hematology at the Cleveland Clinic Taussig Cancer Center; and Ms. Phyllis McKiernan, Advanced Practice Nurse, John Theurer Cancer Center, Hackensack Meridian Health.
In the first segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, evaluates guideline recommendations for the management of patients with advanced diffuse large B-cell lymphoma (DLBCL). Learners will receive expert insight on assessing emerging data on novel therapies, strategies to manage adverse events, and optimizing treatment for patients with advanced DLBCL. Complete modules 2 and 3 for more in-depth knowledge of aggressive non-Hodgkin lymphoma. Start now!
In the second segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD Anderson Cancer Center, shares expert insights on guideline recommendations for optimizing individual patient care, efficacy and safety data, and strategies to manage adverse event for patients with advanced aggressive mantle cell lymphoma (MCL). For more expert insights on aggressive non-Hodgkin lymphoma, complete modules 1 and 3. Start the activity now!
In the third segment of this three-part series, Maria Badillo, MSN, RN, OCN®, CCRP, Research Nurse Manager, MD, Anderson Cancer Center, evaulates guideline recommendations for the management of peripheral T-cell lymphoma (PTCL), assesses emerging data on novel therapies, and applies strategies to optimize treatment experiences for patients. For more expert insights on aggressive non-hodgkin lymphoma, complete modules 2 and 3. Start the activity now!
This in-depth discussion, presented by Lipika Goyle, MD, Massachusetts General Hospital, will feature expert insights on emerging therapeutic treatments, recent discoveries on novel therapies, managing strategies for monitoring and managing adverse events, and much more! Start the activity now!
Discover new developments in the diagnosis and treatment of EGFR exon-20 Insertion–Mutant NSCLC and assess emerging efficacy and safety data on novel targeted therapies. This activity features expert insights from Helena Yu, MD, Memorial Sloan Kettering Cancer Center, and Maria Arcila, MD, Memorial Sloan Kettering Cancer Center. Start now!
In this CME/NCPD activity, D. Ross Camidge, MD, PhD, of the University of Colorado, and Beth Sandy, MSN, CRNP, OCN®, of the University of Pennsylvania, discuss novel treatments for advanced KRAS mutation-positive NSCLC and how to manage adverse events associated with small molecule inhibitors. Start now!
In the first part of this two-part series, Corey S. Cutler, MD, MPH, FRCPC, shares insights on criteria to appropriately diagnose, grade, and stage graft-versus-host disease (GVHD). Complete part two to hear Dr. Cutler discuss prophylactic strategies for patients undergoing a transplant at high risk for GVHD, emerging data and guideline recommendations in individualized treatment plans for patients with acute and chronic GVHD, and case studies on GVHD. Start now!
In this activity, Oliver Sartor, MD, discusses patient and tumor characteristics that can inform tailored therapeutic approaches for patients with metastatic HSPC, evaluates emerging data on novel treatment combinations and sequences for patients with metastatic HSPC, and assesses strategies to optimize the safety and tolerability of novel therapies for metastatic HSPC. Start now to earn free CME/NCPD!
Learn more about emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events in patients with advanced MCC in this activity presented by Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAO. Start now to earn CME/NCPD!
In this NCPD activity, Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, identifies prognostic markers that impact treatment selection and treatment goals to individual patients with metastatic breast cancer (MBC), evaluates the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC, and more. Complete the activity now to earn free NCPD!
This NCPD activity, presented by Laura S. Wood, RN, MSN, OCN®, discusses mechanisms of action of IO agents and VEGFR TKIs, efficacy and safety profiles of IO and VEGFR TKI therapies, and strategies to improve treatment tolerability for advanced renal cell carcinoma. Start now!